Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; poloxamer; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide red - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. [invented name] is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. [invented name] is also indicated for the treatment of chronic iron overload in patients with non-transfusiondependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; poloxamer; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide red - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. [invented name] is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. [invented name] is also indicated for the treatment of chronic iron overload in patients with non-transfusiondependent thalassemia syndromes aged 10 years and older.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

boston oncology arabia, saudi arabia - busulfan - concentrate for solution for infusion - 6 mg/ml,

European Union - English - EMA (European Medicines Agency)

pierre fabre medicament - busulfan - hematopoietic stem cell transplantation - antineoplastic agents - busilvex followed by cyclophosphamide (bucy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (hpct) in adult patients when the combination is considered the best available option.busilvex following fludarabine (fb) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (hpct) in adult patients who are candidates for a reduced-intensity conditioning (ric) regimen.busilvex followed by cyclophosphamide (bucy4) or melphalan (bumel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - busulfan -

United States - English - NLM (National Library of Medicine)

woodward pharma services llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.

United States - English - NLM (National Library of Medicine)

waylis therapeutics llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - busulfan - solution for injection - busulfan 60 mg / 10 ml - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - busulfan - film-coated tablet - 2 milligram(s) - alkyl sulfonates; busulfan

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - busulfan - solution for infusion - 6mg/1ml